Modulation of the cellular immune system by intravenous immunoglobulin - PubMed (original) (raw)

Review

. 2008 Dec;29(12):608-15.

doi: 10.1016/j.it.2008.08.004. Epub 2008 Oct 14.

Affiliations

• PMID: 18926775
• DOI: 10.1016/j.it.2008.08.004

Review

Modulation of the cellular immune system by intravenous immunoglobulin

Thanyalak Tha-In et al. Trends Immunol. 2008 Dec.

Abstract

Intravenous immunoglobulin (IVIg) is therapeutically used in a variety of immune-mediated diseases. The beneficial effects of IVIg in auto-antibody-mediated diseases can be explained by neutralization, accelerated clearance and prevention of Fcgamma-receptor binding of auto-antibodies. However, the means by which IVIg exerts therapeutic effects in disorders mediated by cellular immunity have remained enigmatic. Clinical improvements, followed by IVIg treatment, often extend beyond the half-life of infused IgG, thereby indicating that IVIg modifies the cellular immune compartment for a prolonged period. Here, we discuss recent advances in the understanding of different, mutually non-exclusive mechanisms of action of IVIg on cells of the innate and adaptive immune system. These mechanisms might explain the beneficial effects of IVIg in certain autoimmune and inflammatory diseases.

PubMed Disclaimer

Similar articles

• Mechanisms of action of intravenous immune globulin in immune-mediated diseases.
  Mouthon L, Kaveri SV, Spalter SH, Lacroix-Desmazes S, Lefranc C, Desai R, Kazatchkine MD. Mouthon L, et al. Clin Exp Immunol. 1996 May;104 Suppl 1:3-9. Clin Exp Immunol. 1996. PMID: 8625540 Review.
• Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia.
  Crow AR, Song S, Siragam V, Lazarus AH. Crow AR, et al. Pediatr Blood Cancer. 2006 Oct 15;47(5 Suppl):710-3. doi: 10.1002/pbc.20980. Pediatr Blood Cancer. 2006. PMID: 16933274 Review.
• IVIG therapy: interfering with interferon-gamma.
  Clynes R. Clynes R. Immunity. 2007 Jan;26(1):4-6. doi: 10.1016/j.immuni.2007.01.006. Immunity. 2007. PMID: 17241954 Review.
• [Use of intravenous polyclonal immunoglobulins in autoimmune and inflammatory disorders].
  Graff-Dubois S, Sibéril S, Elluru S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV. Graff-Dubois S, et al. Transfus Clin Biol. 2007 May;14(1):63-8. doi: 10.1016/j.tracli.2007.04.003. Epub 2007 May 10. Transfus Clin Biol. 2007. PMID: 17498995 Review. French.

Cited by

• Early Additional Immune-Modulators for Mycoplasma pneumoniae Pneumonia in Children: An Observation Study.
  Youn YS, Lee SC, Rhim JW, Shin MS, Kang JH, Lee KY. Youn YS, et al. Infect Chemother. 2014 Dec;46(4):239-47. doi: 10.3947/ic.2014.46.4.239. Epub 2014 Dec 29. Infect Chemother. 2014. PMID: 25566403 Free PMC article.
• Intravenous immunoglobulin bridging to rituximab in NMDAR encephalitis patients non-responders to first-line treatments.
  Massa F, Franciotta D, Grisanti S, Roccatagliata L, Morbelli S, Beltramini S, Uccelli A, Schenone A, Benedetti L. Massa F, et al. Neurol Sci. 2022 Nov;43(11):6441-6447. doi: 10.1007/s10072-022-06313-3. Epub 2022 Aug 11. Neurol Sci. 2022. PMID: 35953578 Free PMC article.
• Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia.
  Guhr T, Bloem J, Derksen NI, Wuhrer M, Koenderman AH, Aalberse RC, Rispens T. Guhr T, et al. PLoS One. 2011;6(6):e21246. doi: 10.1371/journal.pone.0021246. Epub 2011 Jun 23. PLoS One. 2011. PMID: 21731683 Free PMC article.
• Intravenous immunoglobulin treatment for patients with severe COVID-19: a retrospective multicentre study.
  Liu J, Chen Y, Li R, Wu Z, Xu Q, Li Z, Annane D, Feng H, Huang S, Guo J, Zhang L, Ye X, Zhu W, Du H, Liu Y, Wang T, Chen L, Wen Z, Teboul JL, Chen D. Liu J, et al. Clin Microbiol Infect. 2021 Oct;27(10):1488-1493. doi: 10.1016/j.cmi.2021.05.012. Epub 2021 May 19. Clin Microbiol Infect. 2021. PMID: 34020032 Free PMC article.
• Intravenous immunoglobulin replacement therapy in the treatment of patients with common variable immunodeficiency disease: an open-label prospective study.
  Kasztalska K, Ciebiada M, Cebula-Obrzut B, Górski P. Kasztalska K, et al. Clin Drug Investig. 2011;31(5):299-307. doi: 10.1007/BF03256928. Clin Drug Investig. 2011. PMID: 21473654

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database